Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Stifel analysts increased the price target on Nurix Therapeutics Inc . (NASDAQ:NRIX) shares to $36.00, up from the previous target of $34.00, while reaffirming their Buy rating on the stock. The ...

H.C. Wainwright adjusted their valuation of Nurix shares, increasing the price target from $35.00 to $36.00, while reaffirming a Buy rating on the stock. According to InvestingPro data, analysts ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and ...

The company, named Manas AI, will first focus on breast cancer, prostate cancer and lymphoma before broadening its scope to include other illnesses.